Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose of BI 655130 in Healthy Male and Female Subjects (Open-label, Parallel Group Design)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs BI 655130 (Primary) ; BI 655130 (Primary)
- Indications Pustular psoriasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 12 Jul 2017 Planned End Date changed from 18 Dec 2017 to 29 Dec 2017.
- 12 Jul 2017 Planned primary completion date changed from 18 Dec 2017 to 29 Dec 2017.
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.